Immunotherapies for Neurological Disorders
Unlocking the Brain's Defenses
- 1st Edition - August 1, 2026
- Latest edition
- Editors: Akash Gautam, Micaela Morelli
- Language: English
Immunotherapies for Neurological Disorders: Unlocking the Brain's Defenses explores the complex intersection of both the immune and nervous systems and neurological disord… Read more
Aimed at neurologists, immunologists, researchers, and students alike, this book serves as an essential resource for the latest advancements in neurological disease treatment.
- Examines innovative treatment strategies, including antibodies, recombinant proteins, and vaccines
- Reviews the therapeutic potential of immune cells, gene therapy, and RNA interference in addressing various neurological conditions
- Highlights the latest advancements in immunology relevant to neurodegenerative and autoimmune diseases
2. Harnessing Antibodies for Treating Neurological Disorders
3. Strategies for Suppressing Immune Responses in the Brain
4. Modulating Brain Immunity with Recombinant Proteins
5. Peptides and Their Ligands: A New Frontier in Immunomodulation
6. Vaccines for Neurological Disorders: Preventive Strategies
7. DNA Vaccination for Neurological Disorders: A Promising Approach
8. Therapeutic Potential of Immune Cells for Neurological Disorders
9. Gene Therapy in Neurological Disorders: Modulating Immune System
10. RNA Interference in Neurological Disorders: Silencing Harmful Immune Responses
11. Nanotechnology and Immune Cells: Innovations in Therapy
- Edition: 1
- Latest edition
- Published: August 1, 2026
- Language: English
AG
Akash Gautam
MM
Micaela Morelli
Professor Micaela Morelli is a professor of pharmacology. She joined the Center of Excellence on Neurobiology of Dependence in 2001. She became the Italian representative for the International Brain Research Organization (IBRO) in 2005 and was appointed the councilor of IBRO Western Europe Regional Committee in 2010.
She has dedicated her research interests to the study of drugs active in the central nervous system and particularly to drugs for the treatment of Parkinson’s disease.
These studies have evidenced that blockade of adenosine A2A receptors play a positive role in the symptomatic treatment of Parkinson’s disease. Behavioral studies on this topic have been correlated to specific modifications in zif-268, A2A receptors, dynorphin, enkephalin and GAD67 mRNA in the striatum. Moreover the neuroprotective and anti-inflammatory effects of A2A receptor antagonists have been evidenced in MPTP-treated pre-clinical models. These studies have resulted in clinical trials on A2A receptor antagonists in Parkinson’s patients.